Detalles de la búsqueda
1.
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.
Bioorg Med Chem
; 71: 116947, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35926325
2.
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Cancer Immunol Immunother
; 67(3): 381-392, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29124315
3.
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
J Med Chem
; 67(6): 4936-4949, 2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38477582
4.
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Cancer Discov
; 13(11): 2412-2431, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552839
5.
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5â¢MTA Complex for the Treatment of MTAP-Deleted Cancers.
J Med Chem
; 65(3): 1749-1766, 2022 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35041419
6.
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.
Mol Cancer Ther
; 20(6): 975-985, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33722854
7.
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Cancer Discov
; 10(1): 54-71, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31658955
8.
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Clin Cancer Res
; 23(21): 6661-6672, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28765324
Resultados
1 -
8
de 8
1
Próxima >
>>